GlassScriptPhysician profile
Brittany A Alloway
NPI 1386037240
$3,292.97
in general payments reported to CMS, 2019-2025
30 companies · $981 in 2025
The $981 reported for 2025 was more than what 91% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $109 · 2021: $424 · 2022: $192 · 2023: $626 · 2024: $961 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536 · Education: $31.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.75 |
| Education | $31.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $429.70 | 2020-2025 | |
| Abbvie INC. | $428.28 | 2021-2025 | Linzess, Viberzi, Ubrelvy |
| Lilly USA, LLC | $274.50 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $257.96 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $255.39 | 2021-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $252.37 | 2020-2025 | Shingrix, Bexsero, Pediarix |
| Exact Sciences Corporation | $211.17 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $130.52 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.63 | 2021-2025 | Jardiance, Spiriva Respimat |
| Boston Scientific Corporation | $126.14 | 2021-2025 | Watchman Access System, Wavewriter Alpha Prime 16 |
| Bayer Healthcare Pharmaceuticals INC. | $80.33 | 2021-2023 | |
| Sanofi Pasteur INC. | $78.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $77.58 | 2024-2025 | Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $72.52 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $53.75 | 2021-2024 | Spravato |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $52.65 | 2024 | |
| Sanofi-Aventis U.S. LLC | $41.51 | 2024-2025 | |
| Mylan Specialty L.P. | $40.30 | 2023 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $39.09 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $36.57 | 2025 | Sunosi, Auvelity |
| Amarin Pharma, INC. | $35.39 | 2020 | |
| Edwards Lifesciences Corporation | $32.05 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Madrigal Pharmaceuticals | $28.76 | 2025 | Rezdiffra |
| Viiv Healthcare Company | $24.64 | 2025 | Apretude |
| Exeltis, USA INC. | $24.06 | 2025 | Slynd |
| Xeris Pharmaceuticals, INC. | $23.26 | 2023 | Gvoke Hypopen |
| Gilead Sciences, INC. | $15.87 | 2023 | |
| Nestle Healthcare Nutrition INC. | $15.13 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.13 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Alloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.